Have to get the complete breakdown of the numbers
Post# of 154646
(Total Views: 681)
Posted On: 07/19/2021 8:26:36 AM
Have to get the complete breakdown of the numbers but it looks like we might have the last approved mTNBC drug beat.
Quote:
In all patients who were randomized in the study, including the brain metastases population, Sacituzumab govitecan lead to a median PFS of 4.8 months (95% CI, 4.1-5.compared with 1.7 months (95% CI, 1.5-2.5) in patients who received chemotherapy (HR, 0.43; 95% CI: 0.35-0.54; P <.0001). In addition, the median OS was 11.8 months (95% CI, 10.5-13.
Sacituzumab govitecan also achieved an ORR of 35% in patients with mTNBC versus 5% for with physician’s choice of therapy (P <.0001).
Quote:
In the brain metastasis population, the ORR was 3% with sacituzumab govitecan compared with 0% with chemotherapy, and the disease control rates were 9% and 3%, respectively. The analysis also showed stable disease (SD) in 47% and 31% in Sacituzumab govitecan and chemotherapy arms, respectively, but SD was not long-lasting.
In terms of survival, the median PFS was 2.8 months (95% CI, 1.5-3.9) with sacituzumab govitecan and 1.6 months (95% CI, 1.3-2.9) with chemotherapy (HR, 0.65; 95% CI, 0.35-1.22). At 3 months, the PFS rate was 41.4% with the ADC and 27.7% with chemotherapy. By 9 months the corresponding PFS rates were 9.0% and 0%.
In addition, a modest difference in OS was observed between the 2 study arms. The median OS was 6.8 months (95% CI, 4.7-14.1) with sacituzumab govitecan and 7.5 months (95% CI, 4.7-11.1) with physician’s choice of treatment (HR, 0.87; 95% CI, 0.47-1.63).
(13)
(0)